The initial anti-GRIM-19 activities came from studies on human Herpesvirus-8 (HHV-8) that is frequently associated with Kaposi’s sarcoma (KS), B-cell Lymphoma (BCL), multicentric castleman disease (MCD) and primary effusion lymphoma (PEL) (Gillison and Ambinder, 1997; Neipel and Fleckenstein, 1999). Here, NDUFA13 is linked to primary effusion lymphoma.